DS
AKBA icon

DRW Securities’s Akebia Therapeutics AKBA Stock Holding History

DRW Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15.9K Buy
+11,443
New +$15.7K ﹤0.01% 1217
2025
Q4 		– Sell
-67,824
Closed -$185K – 1216
2025
Q3 		$185K Buy
67,824
+57,142
+535% +$190K ﹤0.01% 1101
2025
Q2 		$38.9K Buy
+10,682
New +$29.4K ﹤0.01% 1044
2024
Q2 		– Sell
-21,000
Closed -$38.4K – 517
2024
Q1 		$38.4K Buy
+21,000
New +$33.6K ﹤0.01% 366

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

DRW Securities's AKBA Position: Q1 2026 in Review

DRW Securities opened a new position in Akebia Therapeutics (AKBA) in Q1 2026: 11,443 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #1217 among its holdings. This is a return to the name: DRW Securities previously reported a position in AKBA as recently as Q3 2025.

DRW Securities first reported a position in AKBA in Q1 2024 and has held it in 4 quarters since. The position peaked at $185K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • DRW Securities held 11,443 shares of Akebia Therapeutics worth $15.9K as of Q1 2026.
  • Akebia Therapeutics was a new DRW Securities position in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1217 holding.
  • DRW Securities first reported a position in Akebia Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • DRW Securities's Akebia Therapeutics position peaked at $185K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.